



*5FW*  
PATENT

Case Docket No. ORYXE.001C2  
Date: June 22, 2004


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :	Frederick L. Jordan
Appl. No. :	10/789,836
Filed :	February 27, 2004
For :	A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS
Examiner :	Unassigned
Group Art Unit :	Unassigned

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 22, 2004

(Date)

  
Eric S. Furman, Ph.D., Reg. No. 45,664

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- An Information Disclosure Statement.
- A PTO Form 1449 listing seventy-one (71) references, only of which twenty-nine (29) are enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- Return prepaid postcard.

  
Eric S. Furman, Ph.D.  
Registration No. 45,664  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550



### INFORMATION DISCLOSURE STATEMENT

Applicant : Frederick L. Jordan  
 App. No. : 10/789,836  
 Filed : February 27, 2004  
 For : A MIXTURE FOR TRANSDERMAL  
 DELIVERY OF LOW AND HIGH  
 MOLECULAR WEIGHT COMPOUNDS  
 Examiner : Unassigned  
 Group Art Unit : Unassigned

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing seventy-one (71) references. References numbered 1-37, 43-45, 68 and 70 are of record in U.S. patent application No. 10/183,764, filed June 25, 2002, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Accordingly, copies of references numbered 1-37, 43-45, 68 and 70 are not submitted pursuant to 37 C.F.R. § 1.98(d). There are a total of twenty-nine (29) references that are enclosed. Those references are numbered 38-42, 46-67, 69 and 71.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/22/04

By: E.S.F.

Eric S. Furman, Ph.D.  
 Registration No. 45,664  
 Attorney of Record  
 Customer No. 20,995  
 (619) 235-8550

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. ORYXE.001C2	APPLICATION NO. 10/789,836
O P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT Frederick L. Jordan	
JUN 25 2004 (USE SEVERAL SHEETS IF NECESSARY)			FILING DATE February 27, 2004	GROUP Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
1	5,318,960	06/07/94	Toppo			
2	5,431,924*	07/11/95	Ghosh et al.			
3	5,472,713	12/05/95	Fein et al.			
4	5,571,671	11/05/96	Potter			
5	5,614,212	03/25/97	D'Angelo et al.			
6	5,665,378	09/09/97	Davis et al.			
7	5,708,038	01/13/98	Davis			
8	5,716,625	02/10/98	Hahn et al.			
9	5,744,368	04/28/98	Goldbager et al.			
10	5,837,853	11/17/98	Takashima et al.			
11	5,840,746	11/24/98	Ducharme et al.			
12	5,849,334	12/15/98	Rivlin			
13	5,861,268	01/19/99	Tang et al.			
14	5,885,597	03/23/99	Botknecht et al.			
15	5,891,651	04/06/99	Roche et al.			
16	5,891,857	04/06/99	Holt et al.			
17	5,958,384	09/28/99	Holick			
18	6,103,246	08/15/00	Tisdale et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
19	92/08470	05/29/92	WO				
20	97/09992 A1	03/20/97	WO				
21	98/03163	01/29/98	WO				
22	98/33474	08/06/98	WO				
23	98/34629	08/13/98	WO				

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ORYXE.001C2	APPLICATION NO. 10/789,836
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Frederick L. Jordan	
JUN 25 2004 (USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 27, 2004	GROUP Unassigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
24	Aloe Laboratories, Manufacturing Procedures, Product: Regular Traditional Hand Fillet Aloe Vera Juice, 1 page, date unknown.
25	Amadio et al., Nonsteroidal anti-inflammatory drugs, Postgraduate Medicine, 93(4):73-97 (1993).
26	Barel and Clarys, Study of the Stratum corneum Barrier Function by Transepidermal Water Loss Measurements: Comparison between Two Commercial Instruments, Skin Pharmacol., 8:186-195 (1995).
27	Biomedical Information Services, Ltd., Inspection Criteria, General Standard for Testing Purity of Aloe Vera, 7 pages, Copyright 1996:
28	Bronaugh and Collier, In vitro Percutaneous absorption studies: Principle, Fundamentals, and Applications, eds., Bronaugh and Maibach, Boca Raton, FL, CRC Press, pp. 237-241 (1991).
29	Chattem Inc., Packaging – Flexall QuickGel, Copyright 1999.
30	Cohen et al., in Wound Healing/Biochemical and Clinical Aspects, 1 <sup>st</sup> ed. WB Saunders, Philadelphia (1992).
31	Collier et al., Maintenance of Skin Viability during in Vitro Percutaneous Absorption/Metabolism Studies, Toxicology and Applied Pharmacology, 99:522-533 (1989).
32	Downing et al., Dermatology in General Medicine, Fitzpatrick, et al., eds., pp. 210-221 (1993).
33	Grindlay and Reynolds, The Aloe Vera Phenomenon: A Review of the Properties and Modern Uses of the Leaf Parenchyma Gel, J. of Ethnopharmacology, 16:117-151 (1986).
34	Hart et al., "Two Functionally and Chemically Distinct Immunomodulatory Compounds in the Gel of Aloe Vera," J. of Ethnopharmacology, 23:61-71 (1988).
35	Hirata et al., "biologically Active Constituents of Leaves and Roots of the Aloe Vera Arborescens var. natalensis," Z. Naturforsch, 32c:731-734 (1977).
36	<a href="http://www.natplus.com/products/productNumber=7124">http://www.natplus.com/products/productNumber=7124</a> .
37	<a href="http://www.botanical.com/botanical/mgmh/f/franki3l.html">http://www.botanical.com/botanical/mgmh/f/franki3l.html</a> .
38	Informational Packet, Sederma, Melaslow™, pp. 1-28, 12/00.
39	Informational Packet, Sederma, Ichtyocollagene, pp. 1-19, 08/93.
40	Informational Packet, Sederma, Etioline, pp. 1-14, 10/96.
41	Informational Packet, Sederma, Matrixyl, pp. 1-44, 09/99.
42	Informational Packet, "Guide to Specialty Ingredients for the Personal Care Industry," CRODA, 15 <sup>th</sup> Anniversary Issue, pp. 1-42, 2000.
43	International Aloe Science Council, Inc., The Datasheet – 100% Pure Aloe Vera, 1 page, date unknown.
44	Nelson et al., "MidInfrared Laser Ablation of Stratum Corneum Enhances in Vitro Percutaneous Transport of Drugs," The Society for Investigative Dermatology, Inc., pp. 874-879 (1991).
45	O'Malley et al., "Emu Products, Increasing Production and Profitability," Rural Industries Research & Development Corporation, pp. i-110 (12/99).
46	Pamphlet – <i>The mighty macadamia</i> , SPC ASIA, March 2000.
47	Pamphlet – Certificate of Analysis for Florasolvs® PEG-16 Macadamia, June 2001.
48	Pamphlet – Life Extension™, April 2002.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ORYXE.001C2	APPLICATION NO. 10/789,836
		APPLICANT Frederick L. Jordan	
		FILING DATE February 27, 2004	GROUP Unassigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
49	Pamphlet – <i>In a Nutshell</i> , Reprinted from SPC, May 1999.
50	Pamphlet – <i>A natural alternative</i> , Reprinted from SPC Asia, May 1999.
51	Pamphlet – <i>Melaslow™</i> .
52	Pamphlet – Patent N FR 00.11002 Melaslow™.
53	Product Specification for FLORAESTERS® 20, March 1997.
54	Product Specification for FLORAESTERS® 30, March 1997.
55	Product Specification for FLORAESTERS® 60, March 1998.
56	Product Specification for FLORAESTERS® 70, June 1997.
57	Product Specification for FLORASOLVS® PEG-10 Sunflower, June 1999.
58	Product Specification for FLORASUN® 90, Refined, Bleached, Winterized, Deodorized, January 2000.
59	Product Specification for FLORAESTERS® IPJ, February 2000.
60	Product Specification for FLORAESTERS® HIPJ, October 1999.
61	Product Specification for FLORABEADS®, JOJOBA 40/60, September 1999.
62	Product Specification for FLORABEADS®, JOJOBA White 60/100, March 1998.
63	Product Specification for FLORASOLVS® PEG-80 Jojoba, June 1999.
64	Product Specification for FLORASOLVS® PEG-120 Jojoba, October 1999.
65	Product Specification for FLORAESTERS®, JOJOBA OIL, Pasteurized, Not Refined, January 2000.
66	Product Specification for FLORAESTERS® 15, December 1998.
67	Product Specification for FLORABEADS®, JOJOBA 28/60, September 1999.
68	Ponec, M., "Epidermal lipids <i>in vivo</i> ," The Keratinocyte Handbook, Leigh et al., eds, pp. 351-363 (1994).
69	Taguchi et al., "Enhancement of Propylene Glycol Distribution in the Skin by High Purity <i>cis</i> -Unsaturated Fatty Acids with Different Alkyl Chain Lengths Having Different Double Bond Position," Biol. Pharm. Bull., 22(4):407-411 (1999).
70	Woodin, L., "Cutting Postop pain," RN, pp. 26-33 (1993).
71	<a href="http://www.essentialoils.co.za/macadamia_oil.htm">http://www.essentialoils.co.za/macadamia_oil.htm</a> , Macadamia oil for massage therapy and to help moisturize the skin, 2001.

S:\DOCS\ESF\ESF-7751.DOC  
042204

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	